home / stock / celc / celc quote
Last: | $18.16 |
---|---|
Change Percent: | -1.03% |
Open: | $17.7 |
Close: | $18.16 |
High: | $18.2 |
Low: | $17.25 |
Volume: | 196,014 |
Last Trade Date Time: | 03/27/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$18.16 | $17.7 | $18.16 | $18.2 | $17.25 | 196,014 | 03-27-2024 |
$17.52 | $17.81 | $17.52 | $18.2 | $17.48 | 180,189 | 03-26-2024 |
$17.8 | $17.93 | $17.8 | $18.7099 | $17.77 | 83,853 | 03-25-2024 |
$17.78 | $17.48 | $17.78 | $17.84 | $17.38 | 88,729 | 03-22-2024 |
$17.62 | $17.87 | $17.62 | $18.1 | $17.49 | 326,122 | 03-21-2024 |
$17.79 | $18 | $17.79 | $18.29 | $17.35 | 640,867 | 03-20-2024 |
$18 | $17.84 | $18 | $18.09 | $17.66 | 64,190 | 03-19-2024 |
$17.83 | $17.85 | $17.83 | $18 | $17.54 | 287,565 | 03-18-2024 |
$17.75 | $17.68 | $17.75 | $18.06 | $17.31 | 268,932 | 03-15-2024 |
$17.81 | $18.05 | $17.81 | $18.05 | $17.4 | 515,924 | 03-14-2024 |
$17.96 | $17.82 | $17.96 | $18.37 | $17.69 | 498,907 | 03-13-2024 |
$17.85 | $17.75 | $17.85 | $18.18 | $17.56 | 1,036,400 | 03-12-2024 |
$17.9 | $18.57 | $17.9 | $18.57 | $17.81 | 638,428 | 03-11-2024 |
$18.56 | $18.16 | $18.56 | $18.95 | $18.13 | 187,041 | 03-08-2024 |
$17.94 | $18.38 | $17.94 | $18.665 | $17.72 | 126,047 | 03-07-2024 |
$18.19 | $18.41 | $18.19 | $18.41 | $17.92 | 60,440 | 03-06-2024 |
$18.2 | $18.44 | $18.2 | $18.93 | $18.09 | 93,411 | 03-05-2024 |
$18.49 | $17.7 | $18.49 | $18.55 | $17.25 | 309,942 | 03-04-2024 |
$17.43 | $15.46 | $17.43 | $17.45 | $15.46 | 392,465 | 03-01-2024 |
$15.56 | $16.02 | $15.56 | $16.175 | $15.1 | 343,783 | 02-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $24.00 for CELC on 2024-03-28 07:08:00. The adjusted price target was set to $24.00. At the time of the announcement, CELC was trading at $18.16. CELC currently trades -4.12% versus its 52 week high of...
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data demonstrating the superior therapeutic effects of gedatolisib compared to other PI3K/AKT/mT...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...